Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Total Debt (2017 - 2025)

Serina Therapeutics (SER) has disclosed Total Debt for 9 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • Quarterly Total Debt fell 74.11% to $2.9 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Sep 2025, down 74.11% year-over-year, with the annual reading at $18.1 million for FY2022, 37.28% up from the prior year.
  • Total Debt hit $2.9 million in Q3 2025 for Serina Therapeutics, down from $11.2 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $33.0 million in Q2 2023 to a low of $2.2 million in Q3 2023.
  • Historically, Total Debt has averaged $13.4 million across 5 years, with a median of $11.2 million in 2024.
  • Biggest five-year swings in Total Debt: crashed 85.82% in 2023 and later soared 402.7% in 2024.
  • Year by year, Total Debt stood at $13.2 million in 2021, then skyrocketed by 37.28% to $18.1 million in 2022, then plummeted by 87.76% to $2.2 million in 2023, then skyrocketed by 402.7% to $11.2 million in 2024, then crashed by 74.11% to $2.9 million in 2025.
  • Business Quant data shows Total Debt for SER at $2.9 million in Q3 2025, $11.2 million in Q3 2024, and $11.1 million in Q2 2024.